Trial Summary
What is the purpose of this trial?The purpose of this study is to compare treatment of sebaceous hyperplasia with pulsed dye laser (PDL) plus neodymium doped yttrium aluminum garnet laser (Nd:YAG) versus erbium doped yttrium aluminum garnet (erbium:YAG) laser versus electrodesiccation and curettage (ED\&C).
This is a randomized clinical trial. Approximately 18 participants will enrolled. Each participant will have their sebaceous hyperplasia lesions randomized to receive either Erbium:YAG, PDL plus Nd:YAG, or ED\&C treatment. Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Lesions will be treated twice, 2-6 weeks after the first treatment. Lesion size and count will be measured before treatment and at follow-up 4-12 weeks after the first treatment. This study is a pilot study designed to determine the feasibility of these procedures.
Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.
Eligibility Criteria
This trial is for adults over 18 in good health living in the Chicago area, seeking cosmetic treatment for sebaceous hyperplasia. They must understand and sign a consent form. Excluded are those with poor wound healing, recent sun exposure affecting skin pigment, pregnant or nursing individuals, and anyone unable to communicate or cooperate due to language barriers or mental impairment.Inclusion Criteria
I am 18 years old or older.
Exclusion Criteria
I can communicate and cooperate with the study team.
Treatment Details
The study compares three treatments for sebaceous hyperplasia: Pulsed Dye Laser (PDL) plus Nd:YAG Laser; Erbium:YAG Laser; and Electrodessication & Curettage (ED&C). Each participant's lesions will be randomly assigned one of these treatments. Lesions get treated twice within 2-6 weeks and results are checked after 4-12 weeks.
3Treatment groups
Active Control
Group I: ED&C treatmentActive Control1 Intervention
Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
Group II: Erbium:YAG LaserActive Control1 Intervention
Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
Group III: PDL plus Nd:YAGActive Control2 Interventions
Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
Find a clinic near you
Research locations nearbySelect from list below to view details:
Northwestern University Department of DermatologyChicago, IL
Loading ...
Who is running the clinical trial?
Northwestern UniversityLead Sponsor